About
Prior to joining Burrill, Dr. Wu held professional positions with Edwards Lifesciences and Eli Lilly & Company. She was Director of Strategy at Edwards, responsible for the strategic planning in the biologics program. At Eli Lilly & Company Oncology and Integrated Biology, Dr. Wu oversaw finance, business development, pipeline valuation, organizational restructure and outsourcing strategy. She also worked at Eli Lilly’s M&A Group and with Oncology Discovery Research. Dr. Wu founded BioHorizon, a consultancy focused on value creation in the life sciences industry across the Pacific Rim. She advised a number of biotech start-ups and venture capital firms. Dr. Wu’s scientific expertise centers on basic and clinical research in oncology and neuroscience. She was selected by Nobel Laureate Dr. Marshall Nirenberg as an IRTA Fellow at the National Institutes of Health (NIH). Dr. Wu received her M.D. from Shanghai Second Medical University, a Ph.D. in Medical Sciences from Medical College of
Position in the VCSift Database
- • 2 investors at Quan Capital are tracked.
- • 1,801 investors hold the Managing Director role in VCSift. Marietta Wu is one of them.
- • 49 investors are based in Shanghai, China.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Shanghai, China
Contact Information
Find more investors like Marietta
Search Investors